159 related articles for article (PubMed ID: 28592523)
21. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
22. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
[TBL] [Abstract][Full Text] [Related]
23. Detection of a rare CDKN2A intronic mutation in a Hungarian melanoma-prone family and its role in splicing regulation.
Balogh K; Széll M; Polyánka H; Pagani F; Bussani E; Kemény L; Oláh J
Br J Dermatol; 2012 Jul; 167(1):131-3. PubMed ID: 22292911
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
25. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z; Lim SY; Rizos H
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
[TBL] [Abstract][Full Text] [Related]
26. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
27. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
[TBL] [Abstract][Full Text] [Related]
28.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
29. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Manoukian S; Peissel B; Pensotti V; Barile M; Cortesi L; Stacchiotti S; Terenziani M; Barbera F; Pasquini G; Frigerio S; Pierotti MA; Radice P; Della-Torre G
Eur J Cancer; 2007 Feb; 43(3):601-6. PubMed ID: 17224268
[TBL] [Abstract][Full Text] [Related]
30. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
33. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
[TBL] [Abstract][Full Text] [Related]
34. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
35. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
[TBL] [Abstract][Full Text] [Related]
37. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
38. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.
Helgadottir H; Höiom V; Jönsson G; Tuominen R; Ingvar C; Borg A; Olsson H; Hansson J
J Med Genet; 2014 Aug; 51(8):545-52. PubMed ID: 24935963
[TBL] [Abstract][Full Text] [Related]
39. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
